🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

.Manju George MVSc PhD Rectal Cancer Survivor highlights the value and community of Colontown to patients with CRC and caregivers. Love seeing this group get praise. #GI24

#ASCO2025 abstracts are out! So many great talks and studies. A few I'm really looking forward to: 1. ATOMIC. dMMR stage III CRC addition of Atezolizumab. Finally addressing checkpoint in the adjuvant setting? 2. MATTERHORN. GC/GEJC addition of Durva to FLOT. Its a plenary...

Dr. Rakesh K. Jain honored with #AACR25 Lifetime Achievement in #CancerResearch for his pioneering contributions to understanding the TME. He shares that his first R01 was rejected 6 times. A great lesson in passion + persistence! Harvard University MassGeneral News AACR

Opening plenary at #AACR25 Dr Pat LaRusso honors Dr Larry Salzman with the Distinguished Public Service Award. Thank you Dr Salzman for your fierce advocacy for medical research for life threatening diseases.

A powerful moment at #AACR25 as attendees stand together to champion the lifesaving impact of cancer research.

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

Dr Margaret Foti, PhD, MD (hc) presents Tammy Baldwin the #AACR25 Distinguished Public Service Award for her leadership in addressing the growing threats and consequences on patients, researchers, clinicians. Thank YOU Senator Baldwin!

Amazing talk by Anisha Patel @MDanderson about the LUT014 BRAF paradoxical inhibitor for EGFR induced rash!

I think so for colorectal and esophageal, considering also SANO trial, increasingly the question is can we hold off on surgery or reserve for salvage and that answer building “yes” evidence Dr. Nina Niu Sanford

Remote assessment of patients on clinical trial, via telemedicine, opens the door to more widespread enrollment from patients in rural areas and more. APOLLO trial in pancreatic cancer is the first NCI-funded trial to allow this -Shaalan Beg MD MBA FASCO #AACR25 Plenary

Great to hear from Shaalan Beg MD MBA FASCO at this mornings plenary at AACR discussing how to make clinical trials more accessible! One such tactic is decentralization of trials! They require retraining staff, educating patients & leveraging new technologies like AI #AACR25 #AACRSSP

Alberto Bardelli discusses the exposome influences that contribute to early-onset disease. Innovative research in proteomics and molecular profiling will provide new insights into potential preventive, diagnostic and therapeutic strategies.AACR #AACR25 #AACRSSP #crcsm

Early-onset colorectal cancer clinical challenges. A great talk by Cassandra Fritz, MD, MPHS at #AACR2025! #AACR25 #EOCRC

Thank you for sharing such a powerful moment, AACR. It is true that #CancerResearchSavesLives #AACR25

Redefining Cancer Survivorship for People Living with Advanced and Metastatic Cancers. Great session with good practical information. Jill Feldman amazing as always … tells it as it is… #AACR25 #AACRSSP AACR

I think the best part of #PatientAdvocacy for me is being able to interact with brilliant folks like these 2 fantastic women who are changing the world daily!! Thank you both for everything you do! Andrea Cercek Yin Cao #AACR2025 #CRCSM #EOCRC

#ASCO25 is less than 4 weeks away! Honored to be among ASCO’s “Featured Voices,” representing general medical oncologists and our community. Follow these featured voices 👇👇 to stay updated on the latest in oncology!! #OncTwitter #MedTwitter #MedEd Roswell Park Wilmot Cancer Institute

👀Adjuvant aspirin 160 mg for 3 years- now in NCCN for patients with PIK3CA mutated #ColorectalCancer 👉ALASCCA trial showed ⬇️ 3-year recurrence. 👉Results even more impressive in patients with PIK3R1 and PTEN mutant cancers (+DFS benefit) ❓How are oncologists obtaining this

Congrats to Michael LaPelusa, MD for a great study adding to the avalanche of data showing neoadjuvant PDL1 for MSI-H rectal cancer is safe and effective! 3 year followup for pembrolizumab in MSI-H localized rectal cancer Strong use-case for ctDNA monitoring 3-year EFS 92% vs

It's been a month since we moved to MS! I started as an Asst Professor in the Dept of Population Science at the John D Bower School of Pop Health. Also working with UMMC Cancer Center and Research Institute to chair the MS #colorectalcancer Roundtable. To improving #CRC outcomes in MS! Rod Rocconi #CRCSM